Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Antimicrobial Endotracheal Tube to Combat Biofilm

Award Number: R43HL134456
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2016
PERIOD OF PERFORMANCE END DATE: 10/31/2017

Group Awards By:

View Award Description

Antimicrobial Endotracheal Tube to Combat Biofilm - ABSTRACT Ventilator associated pneumonia (VAP) is one of the most costly and deadly nosocomial infections. Over 250,000 cases of VAP occur per year resulting in over 36,000 deaths and a cumulative annual cost to the US Healthcare system over 3 Billion. Endotracheal tubes (ETT) are inserted into the trachea to allow mechanical ventilation. They are a critical part of the ventilator circuit but also provide a conduit for transmission of bacteria to the lungs. Biofilms form rapidly on ETTs and are thought to play a key role in VAP development as well as the antibiotic resistance and persistence commonly seen with VAP. The goal of this project is to develop an innovative antimicrobial endotracheal tube (ETT) that is effective against biofilm producing pathogens associated with VAP. The proposed ETT will be coated with a novel polymer formulation of an engineered cationic antimicrobial peptide (eCAP) previously shown to be effective against drug resistant bacteria common to VAP. The polymer coating will provide controlled eCAP release and protection of the peptide until release. It will also will provide a hydrophilic, biocompatible interface resistant to fouling. The scope of work covers development of the coating formulation and application to ETTs with an evaluation of coating stability and ETT cuff compliance. eCAP release rates and stability in artificial saliva will be measured by RP-HPLC. Feasibility will be demonstrated using Pseudomonas aeruginosa and methicillin resistant Staphylococcus aureus, which are two of the most common causative organisms in VAP. The plan includes studies designed to show prevention of biofilm formation on coated ETTs. The plan also employs an in vitro model that is designed to evaluate the roles that both ETT balloon compliance and bactericidal effect play in preventing bacteria transfer from the throat to the lungs. Finally, cytotoxicity against tracheal epithelial cells will be assessed. If successful, the product is expected to have a significant and sustained impact on reducing morbidity and mortality associated with VAP.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2018 ( Subtotal = $0 )
2018	2016	ALLVIVO VASCULAR, INC.	20914 BAKE PARKWAY SUITE 100	LAKE FOREST	CA	92630	ORANGE	USA	Lung Diseases Research	000	1	3/2/2018	NEW	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $50,000 )
2017	2017	ALLVIVO VASCULAR, INC.	20914 BAKE PARKWAY SUITE 100	LAKE FOREST	CA	92630	ORANGE	USA	Lung Diseases Research	000	1	1/6/2017	SUPPLEMENT FOR EXPANSION	$50,000
														Subtotal = $50,000

Issue Date FY: 2016 ( Subtotal = $224,497 )
2016	2016	ALLVIVO VASCULAR INC	20914 BAKE PARKWAY	LAKE FOREST	CA	92630	ORANGE	USA	Cardiovascular Diseases Research	000	1	7/22/2016	NEW	$224,497
														Subtotal = $224,497

Grand Total All Awards = $274,497

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Antimicrobial Endotracheal Tube to Combat Biofilm

Award Number: R43HL134456

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2016

PERIOD OF PERFORMANCE END DATE: 10/31/2017

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer